Tejara Capital Ltd Acquires New Shares in Enovis Corporation $ENOV

Tejara Capital Ltd purchased a new stake in Enovis Corporation (NYSE:ENOV – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 31,100 shares of the company’s stock, valued at approximately $644,000.

Several other hedge funds have also recently bought and sold shares of ENOV. Arax Advisory Partners acquired a new stake in shares of Enovis in the fourth quarter worth about $29,000. EverSource Wealth Advisors LLC increased its holdings in shares of Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after acquiring an additional 707 shares during the last quarter. Danske Bank A S bought a new position in shares of Enovis in the 3rd quarter valued at approximately $64,000. iSAM Funds UK Ltd acquired a new stake in Enovis in the 3rd quarter worth approximately $80,000. Finally, Brown Brothers Harriman & Co. acquired a new stake in shares of Enovis in the third quarter worth $90,000. 98.45% of the stock is owned by institutional investors and hedge funds.

Get Enovis alerts:

Enovis Trading Down 1.6%

Enovis stock opened at $26.07 on Friday. The business has a 50 day moving average price of $25.13 and a two-hundred day moving average price of $24.14. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84. Enovis Corporation has a 12 month low of $19.14 and a 12 month high of $34.28. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of -1.35 and a beta of 1.34.

Enovis (NYSE:ENOV – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.05. The firm had revenue of $582.78 million for the quarter, compared to the consensus estimate of $581.84 million. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The business’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities analysts forecast that Enovis Corporation will post 3.15 EPS for the current year.

Insider Buying and Selling

In other Enovis news, insider Oliver Engert purchased 1,200 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was purchased at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the purchase, the insider directly owned 51,840 shares in the company, valued at approximately $1,120,780.80. This trade represents a 2.37% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have bought a total of 4,200 shares of company stock worth $92,084 in the last three months. 2.90% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. BTIG Research lifted their price objective on Enovis from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. UBS Group restated a “buy” rating and set a $51.00 target price (up from $50.00) on shares of Enovis in a research note on Tuesday, July 28th. Zacks Research raised Enovis from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 29th. Evercore set a $32.00 price target on Enovis in a report on Monday, July 6th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $30.00 price objective on shares of Enovis in a research report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Enovis presently has a consensus rating of “Moderate Buy” and an average price target of $41.29.

Check Out Our Latest Analysis on Enovis

Enovis Profile

(Free Report)

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

See Also

• Five stocks we like better than Enovis
• 3 Energy Stocks Raising Dividends as the Sector Surges
• 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
• Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
• The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future

Want to see what other hedge funds are holding ENOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enovis Corporation (NYSE:ENOV – Free Report).

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.